✦ LIBER ✦
Brentuximab vedotin in Hodgkin lymphoma and systemic anaplastic large-cell lymphoma: The FDA approval of this novel antibody-drug conjugate is based on durable responses, with no data yet showing improved survival
✍ Scribed by Jame Abraham
- Book ID
- 119219229
- Publisher
- Frontline Medical Communications, Inc.
- Year
- 2012
- Tongue
- English
- Weight
- 108 KB
- Volume
- 9
- Category
- Article
- ISSN
- 1548-5315
No coin nor oath required. For personal study only.